NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis
Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis

NCT02477059

CompletedPhase 3

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions: Hand Osteoarthritis

Interventions: tocilizumab, saline solution

Countries: France

Hand osteoarthritis (HOA) which affects the interphalangeal joints and the metacarpophalangeal of the thumb is a common disease, the prevalence of which being about 30 % of the population over than 70. Some forms of HOA are refractory to usual treatments (analgesics, NSAIDs, local injections) and can lead to a high disability. In vitro and in vivo studies showed that IL-6 is involved in the OA process. The aim of the present study is to assess the efficacy of an Interleukin-6-Receptor Inhibitor (tocilizumab) on pain and function in patients with refractory hand OA.

Eligibility overview

Sex: ALL

Age: 40 Years to 85 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Age: 40-85
* Hand OA according to the ACR criteria (with recent X-rays of the hands - less than 6 months )
* Symptomatic hand OA lasting more than 3 months (DIP or PIP) despite analgesics and NSAIDs
* OA affecting more than three finger joints (DIP or PIP) (Kellgren and Lawrence equal or more than 2)
* Pain intensity superior to 40 (VAS 0-100 mm) in the last 24 hours
* Not breastfeeding throughout the study and for 150 days after the last infusion
* Negative pregnancy test or effective contraception for women of childbearing age throughout the study and for 150 days after the last infusion or postmenopausal or surgically sterile
* Written informed consent
* Affiliated to health system

Exclusion Criteria:

* Patients having already been treated with an anti-TNF alpha within 6 months
* Patients having already been treated with an Interleukin-6-Receptor Inhibitor
* Hand OA secondary to inflammatory rheumatism
* Existence of painful syndrome of upper limbs likely to interfere with the monitoring of pain (cervicobrachial neuralgia, incapacitating carpal tunnel syndrome, joint disorders of the elbow or shoulder)
* Inflammatory rheumatism
* Psoriasis
* Contraindications to Interleukin-6-Receptor Inhibitor
* Contraindications to acetaminophen
* Anticoagulant (oral) or treatment with heparin at a curative dose
* Surgery scheduled within 6 months following recruitment
* Local injection of a corticosteroid in a symptomatic finger joint during the previous month
* Local injection of hyaluronic acid in a symptomatic finger joint during the prior 6 months
* Treatment with a slow-acting anti-osteoarthritis agent initiated within the previous 3 months
* Treatment with methotrexate, hydrochloroquine, sulfasalazine, colchicine within the last month
* History of symptomatics sigmoiditis or intestinal ulceration
* Oral corticosteroid within 3 days for hydrocortisone or cortisone, within 8 days for prednisone, prednisolone, methylprednisolone or triamcinolone, and within 12 days for betamethasone or dexamethasone
* Psychiatric illness
* Antidepressants initiated or modified within previous month
* Non-controlled diabetes "mellitus"
* Known viral hepatitis B or C, HIV infection
* Current infectious (active or latent tuberculosis)
* Excessive drinking
* Participation in another search
* Lidocain plasters on digital joint within two months
Locations (1)
  • Paris, Île-de-France Region, France